Angitia Biopharmaceuticals Announces Topline Results from First in Human Study of AGA2115, A Bispecific Antibody for the Treatment of Osteogenesis Imperfecta
- AGA2115 also received Orphan Drug Designation from European Medicines AgencyWESTLAKE VILLAGE, Calif., June 12, 2025 (GLOBE NEWSWIRE) -- Angitia...